Testing gut bacteria and amino acids to clear hepatitis B surface marker
Part of Digestive system, Infections clinical trials.
This study tests whether a combination of a harmless gut bacterium (Bacteroides fragilis) and branched-chain amino acids (BCAAs, which are building blocks of protein) can help your body clear the hepatitis B surface antigen (HBsAg) from your blood. This may mean moving closer to a functional cure for chronic hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic hepatitis B (a long-lasting liver infection).
- You do not have any active cancer or history of cancer.
- You do not have other liver diseases (like fatty liver, cirrhosis from other causes, etc.).
- You are not pregnant (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.